Goserelin Therapy Before Surgery for Uterine Fibroids

Lumsden, Mary-Ann; West, Christopher C.; Dt, Baird

doi:10.1016/s0140-6736(87)90718-5

Cited by 87 publications

(31 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The maximal GnRH-induced fibroid reduction occurs by 12 weeks, with no further decrease in size noted at 24 weeks (45). It is hypothesized that this is because of the decreased levels of circulating levels of estrogen.…”

Section: Discussionmentioning

confidence: 99%

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Parker

Malik

Catherino

2007

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Parker

Malik

Catherino

2007

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…However, GnRH analogs have been used as preoperative therapy to reduce the size of fibroids prior to hysterectomy; this approach has resulted in reports of significantly less blood loss at operation (Lumsden et al 1987) and increased feasibility of vaginal rather than abdominal hysterectomy, accompanied by shorter hospitalizations (Stovall et al 1991).…”

Section: Clinical Observationsmentioning

confidence: 99%

Etiology and pathogenesis of uterine leiomyomas: a review.

Flake

Andersen

Dixon

2003

Environ Health Perspect

487

392

View full text Add to dashboard Cite

Uterine leiomyomas, or fibroids, represent a major public health problem. It is believed that these tumors develop in the majority of American women and become symptomatic in one-third of these women. They are the most frequent indication for hysterectomy in the United States. Although the initiator or initiators of fibroids are unknown, several predisposing factors have been identified, including age (late reproductive years), African-American ethnicity, nulliparity, and obesity. Nonrandom cytogenetic abnormalities have been found in about 40% of tumors examined. Estrogen and progesterone are recognized as promoters of tumor growth, and the potential role of environmental estrogens has only recently been explored. Growth factors with mitogenic activity, such as transforming growth factor-β 3, basic fibroblast growth factor, epidermal growth factor, and insulin-like growth factor-I, are elevated in fibroids and may be the effectors of estrogen and progesterone promotion. These data offer clues to the etiology and pathogenesis of this common condition, which we have analyzed and summarized in this review.

show abstract

“…Used alone [1,2], they have been shown to reduce both uterine and fibroid volumes. Following discontinua tion of therapy, regrowth of fibroids has been documented [3,4], Their use in combination with surgery, either hys terectomy or myomectomy, has shown some preoperative and operative advantages.…”

Section: Introductionmentioning

confidence: 99%

The Place of Zoladex® in Deferred Surgery for Uterine Fibroids

et al. 1996

View full text Add to dashboard Cite

Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months’ Zoladex® (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group (0.3 g/dl) as well as a tendency towards easier surgery, and reduced operative blood loss. Zoladex-treated patients had a significantly (p = 0.016) shorter hospital stay and pelvic pain and abdominal pressure symptoms were significantly (p < 0.0001) reduced in this group. Zoladex was well tolerated.

show abstract

Goserelin Therapy Before Surgery for Uterine Fibroids

Cited by 87 publications

References 2 publications

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Etiology and pathogenesis of uterine leiomyomas: a review.

The Place of Zoladex® in Deferred Surgery for Uterine Fibroids

Contact Info

Product

Resources

About

Goserelin Therapy Before Surgery for Uterine Fibroids

Cited by 87 publications

References 2 publications

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor

Etiology and pathogenesis of uterine leiomyomas: a review.

The Place of Zoladex&reg; in Deferred Surgery for Uterine Fibroids

Contact Info

Product

Resources

About

The Place of Zoladex® in Deferred Surgery for Uterine Fibroids